The rise of Sildenafil initially sparked a surge for pharma, however recent shifts present a uncertain outlook for investors. Off-patent alternatives are eroding revenue, and persistent legal battles add more https://fanniezoje775247.blogsuperapp.com/41720419/the-blue-pill-and-big-pharma-a-risky-bet